{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T07:12:49Z","timestamp":1723446769806},"reference-count":20,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Pre-eclampsia affects 3-4% of pregnancies and is associated with maternal and infant mortality and morbidity. High-risk pregnancies in Denmark are recommended prophylactic low-dose acetylsalicylic acid (LDA). If new screening algorithms are implemented, LDA will be recommended to around 10% of pregnant women. The use of LDA may slightly increase the risk of minor bleeding disturbances. Otherwise, there is a lot of promising data regarding the safety of LDA use during pregnancy, as argued in this review.<\/jats:p>","DOI":"10.61409\/v10230682","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:17:20Z","timestamp":1715667440000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose acetylsalicylic acid for the prevention of pre-eclampsia"],"prefix":"10.61409","author":[{"given":"Maria F\u00e6rch","family":"Andersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line","family":"Rode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iben Louise Riishede","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Tabor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte Kvist","family":"Ekelund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. Am J Obstet Gynecol. 2022;226(2):S1108-S1119. https:\/\/doi.org\/10.1016\/j.ajog.2020.08.045","DOI":"10.1016\/j.ajog.2020.08.045"},{"key":"ref1","unstructured":"K\u00e4ehne LV, Lundin ICR. Behandling med acetylsalicylsyre kan forebygge pr\u00e6eklampsi hos gravide kvinder i h\u00f8jrisiko. Ugeskr L\u00e6ger. 2017;179:V07160511"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Rode L, Ekelund CK, Riishede I et al. Prediction of pre-term pre-eclampsia according to NICE and ACOG criteria: descriptive study of 597 492 Danish births from 2008 to 2017. Ultrasound Obstet Gynecol. 2021;58(4):561-567. https:\/\/doi.org\/10.1002\/uog.23693","DOI":"10.1002\/uog.23693"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Riishede I, Rode L, Sperling L et al. Pre\u2010eclampsia screening in Denmark (PRESIDE): national validation study. Ultrasound Obstet Gynecol. 2023;61(6):682-690. https:\/\/doi.org\/10.1002\/uog.26183","DOI":"10.1002\/uog.26183"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019;15(5):275-289. https:\/\/doi.org\/10.1038\/s41581-019-0119-6","DOI":"10.1038\/s41581-019-0119-6"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Dimitriadis E, Rolnik DL, Zhou W et al. Pre-eclampsia. Nat Rev Dis Primers. 2023;9(1):8. https:\/\/doi.org\/10.1038\/s41572-023-00417-6","DOI":"10.1038\/s41572-023-00417-6"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019;366:l2381. https:\/\/doi.org\/10.1136\/bmj.l2381","DOI":"10.1136\/bmj.l2381"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Tsiakkas A, Saiid Y, Wright A et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation. Am J Obstet Gynecol. 2016;215(1):87.e1-87.e17. https:\/\/doi.org\/10.1016\/j.ajog.2016.02.016","DOI":"10.1016\/j.ajog.2016.02.016"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Rolnik DL, Wright D, Poon LC et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613-622. https:\/\/doi.org\/10.1056\/NEJMoa1704559","DOI":"10.1056\/NEJMoa1704559"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Dutta S, Kumar S, Hyett J, Salomon C. Molecular targets of aspirin and prevention of preeclampsia and their potential association with circulating extracellular vesicles during pregnancy. Int J Mol Sci. 2019;20(18):4370. https:\/\/doi.org\/10.3390\/ijms20184370","DOI":"10.3390\/ijms20184370"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Loussert L, Vidal F, Parant O et al. Aspirin for preven-tion of preeclampsia and fetal growth restriction. Prenat Diagn. 2020;40(5):519-527. https:\/\/doi.org\/10.1002\/pd.5645","DOI":"10.1002\/pd.5645"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Atallah A, Lecarpentier E, Goffinet F et al. Aspirin for prevention of preeclampsia. Drugs. 2017;77(17):1819-1831. https:\/\/doi.org\/10.1007\/s40265-017-0823-0","DOI":"10.1007\/s40265-017-0823-0"},{"key":"ref12","unstructured":"Ritter JM, Flower R, Henderson G et al. Rang and Dale's pharmacology. 9th ed. Elsevier Health Sciences, 2020"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids. 2004;70(2):223-32. https:\/\/doi.org\/10.1016\/j.plefa.2003.04.010","DOI":"10.1016\/j.plefa.2003.04.010"},{"key":"ref14","unstructured":"Hjertemagnyl. Medicin.dk, 2021. https:\/\/pro.medicin.dk\/Medicin\/Praeparater\/1400# (7 maj 2023)"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Xu Tt, Zhou F, Deng Cy et al. Low-dose aspirin for preventing preeclampsia and its complications: a meta-analysis. J Clin Hypertens (Greenwich). 2015;17(7):567-73. https:\/\/doi.org\/10.1111\/jch.12541","DOI":"10.1111\/jch.12541"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol. 2002;155(1):26-31. https:\/\/doi.org\/10.1093\/aje\/155.1.26","DOI":"10.1093\/aje\/155.1.26"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Duley L, Meher S, Hunter KE et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2019;2019(10):CD004659. https:\/\/doi.org\/10.1002\/14651858.CD004659.pub3","DOI":"10.1002\/14651858.CD004659.pub3"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Hastie R, Tong S, Wikstr\u00f6m AK et al. Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. Am J Obstet Gynecol. 2021;224(1):95.e1-95.e12. https:\/\/doi.org\/10.1016\/j.ajog.2020.07.023","DOI":"10.1016\/j.ajog.2020.07.023"},{"key":"ref19","unstructured":"Abrahamsen K, Andersen AS, Baldur-Felskov B et al. Acetylsalicylsyre i graviditeten. Sandbjerg\/Hindsgavl\/DGCG\/DSFM\/DFS, 2022"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T06:42:21Z","timestamp":1723444941000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V10230682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":20,"URL":"https:\/\/doi.org\/10.61409\/v10230682","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}